5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details
臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-013097-40-ES (EUCTR) | 17/11/2009 | 29/07/2009 | Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada | Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada | Parálisis Supranuclear Progresiva leve o moderada MedDRA version: 9;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy MedDRA version: 9;Level: PT;Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Product Name: NP031112 Product Code: NP031112 800mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | Noscira S.A. | NULL | Not Recruiting | Female: yes Male: yes | 125 | Spain;Germany;United Kingdom | |||
| 2 | EUCTR2009-013097-40-DE (EUCTR) | 06/11/2009 | 30/07/2009 | A double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROS | A double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROS | Mild to Moderate Progressive Supranuclear Palsy MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Product Name: NP031112 Product Code: NP031112 800mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | Noscira S.A. | NULL | Not Recruiting | Female: yes Male: yes | 125 | United Kingdom;Spain;Germany | |||
| 3 | EUCTR2009-013097-40-GB (EUCTR) | 30/10/2009 | 23/07/2009 | A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS | A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS | Mild to Moderate Progressive Supranuclear Palsy MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy | Product Name: NP031112 Product Code: NP031112 600mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione Product Name: NP031112 Product Code: NP031112 800mg Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | Noscira S.A. | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Spain;Germany;United Kingdom |